US FDA conducted a GMP inspection at Piramal Pharma's Sellersville facility from May 4-8, 2026.
The inspection concluded with a Form-483 containing three observations classified as Voluntary Action Indicated.
The company is preparing a detailed response to address the observations for submission to the US FDA.